MediGene and Teva sign supply and licensing agreement

24 February, 2010

MediGene, a German biotechnology company, has signed a licensing and supply agreement with Teva Pharmaceutical Industries for the supply and commercialization of Veregen in Israel. Teva will also be responsible for registering the product in Israel, and upon successful completion of the regulatory procedures, MediGene is entitled to a milestone payment. In addition, MediGene will receive royalties on future sales of the product. Veregen, for the treatment of genital warts, is MediGene's first internally developed drug. Veregen is already available on the US market and has obtained marketing authorization in Germany.